Poor
Needs Revision
Patient Risk:
Info
Summary
Most safety/allergy and dosing-adjacent claims are not supported by the provided label excerpts. Only general triglyceride lowering and cardiovascular risk reduction via VASCEPA are supported; most detailed allergy-symptom and treatment-approach statements are absent from the provided label text.
Category Scores
Accurate Statements
Vascepa works by reducing triglyceride levels in the blood.
Supported by 12.1 Mechanism of Action and 12.2 Pharmacodynamics: VASCEPA reduces TG (including median TG from baseline relative to placebo).
Reducing triglyceride levels with Vascepa can help prevent heart disease and stroke.
Supported by 1 Indications and Usage (reduces risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization) and 14.1 Clinical Studies (reduces cardiovascular events in REDUCE-IT).
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to treat high triglycerides.
Partially supported: label includes adjunct uses for elevated triglycerides and severe hypertriglyceridemia, but the claim is overly general and does not reflect the specific approved indications/adjunct conditions from the provided excerpt.
Vascepa is prescribed for patients with high triglyceride levels, particularly those with a history of heart disease or stroke.
Not fully supported: label excerpt specifies adult patients with elevated TG (≥150 mg/dL) with established CVD or diabetes plus 2+ additional risk factors; it does not state prescribing is particularly for a history of heart disease or stroke.
Some patients taking Vascepa may experience allergy symptoms.
Not supported as stated: the label excerpt addresses potential allergic reactions in patients with known hypersensitivity to fish and/or shellfish, but does not generally state that 'some patients' experience allergy symptoms.
Reported Vascepa allergy symptoms include hives.
Absent from the provided label excerpts; no specific symptom list is included.
Reported Vascepa allergy symptoms include itching.
Absent from the provided label excerpts; no specific symptom list is included.
Reported Vascepa allergy symptoms include swelling of the face, lips, tongue, or throat.
Absent from the provided label excerpts; no specific symptom list is included.
Reported Vascepa allergy symptoms include rash.
Absent from the provided label excerpts; no specific symptom list is included.
Reported Vascepa allergy symptoms can include difficulty breathing in severe cases.
Absent from the provided label excerpts; no specific symptom list is included.
The severity of Vascepa allergy symptoms can vary from person to person.
Absent from the provided label excerpts.
Some patients may experience mild Vascepa allergy symptoms.
Absent from the provided label excerpts.
Other patients may experience more severe Vascepa allergy reactions.
Absent from the provided label excerpts.
A cited source states that Vascepa has a relatively low incidence of allergic reactions, with only 1.4% of patients experiencing an allergic reaction in clinical trials.
Absent from the provided label excerpts; no incidence value for allergic reactions is provided in the supplied excerpts.
Vascepa allergy symptoms are caused by an allergic reaction to Vascepa.
Absent from the provided label excerpts; the label excerpt does not provide mechanistic explanation or symptom causality in these terms.
Taking Vascepa can trigger an immune response leading to the release of histamine and other chemicals that cause allergy symptoms.
Absent from the provided label excerpts; no histamine/immune mechanism explanation is included.
Stopping Vascepa immediately and seeking medical attention is recommended for severe allergy symptoms.
Partially supported: the label excerpt instructs to discontinue and seek medical attention if reactions occur, but the claim is framed specifically for 'severe' allergy symptoms, which is not specified in the provided excerpt.
Antihistamines such as diphenhydramine or loratadine can help relieve mild to moderate Vascepa allergy symptoms.
Absent from the provided label excerpts.
Corticosteroids such as prednisone can help reduce inflammation and swelling associated with Vascepa allergy symptoms.
Absent from the provided label excerpts.
Seeking medical attention is recommended if Vascepa allergy symptoms are severe or persistent.
Partially supported: the label says to discontinue VASCEPA and seek medical attention if reactions occur, but 'severe or persistent' is not stated in the provided excerpt.
It is not possible to completely prevent Vascepa allergy symptoms.
Absent from the provided label excerpts.
Reading the label before taking Vascepa and looking for warnings or precautions can help reduce risk of Vascepa allergy symptoms.
Absent from the provided label excerpts.
Discussing allergies or sensitivities with a doctor before taking Vascepa can help reduce risk of Vascepa allergy symptoms.
Absent from the provided label excerpts.
Starting Vascepa with a low dose and gradually increasing as needed can help reduce risk of Vascepa allergy symptoms.
Contradicted by omission/insufficiency: the provided dosage excerpt does not describe any titration/gradual starting; daily dose is specified as 4 g/day with specific capsule regimens.
Contradictions
Low
AI Statement
Starting Vascepa with a low dose and gradually increasing as needed can help reduce risk of Vascepa allergy symptoms.
Label Reference
2 Dosage and Administration (daily dose specified as 4 grams per day; no titration/gradual start described in provided excerpts).
Important Omissions
Approved indication details: VASCEPA is indicated as an adjunct to maximally tolerated statin therapy to reduce specific cardiovascular risks in adults with elevated TG (≥150 mg/dL) and established CVD or diabetes plus 2+ additional risk factors; and as an adjunct to diet to reduce TG in adults with severe (≥500 mg/dL) hypertriglyceridemia. The response does not accurately include these specific qualifier conditions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The response provides multiple allergy symptom details and treatment suggestions that are not supported by the supplied label excerpts, and it includes a dosing/titration claim not described in the provided dosage section. While it does not introduce contraindications or boxed warnings, unsupported guidance could mislead risk management or use instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Numerous allergy-related specifics (symptom list, incidence, mechanism, and use of specific medications) and a dosing/titration recommendation are absent from the provided FDA label excerpts; only general TG lowering and cardiovascular risk reduction are supported.
Suggested Improvement
Limit allergy content to the label-provided instruction: inform patients with known hypersensitivity to fish and/or shellfish about potential for allergic reactions to VASCEPA and advise discontinuation and seeking medical attention if reactions occur; remove symptom lists, incidence percentages, histamine/mechanism statements, and antihistamine/corticosteroid suggestions; do not add titration/low-dose gradual initiation not described in the dosage instructions.